IL2 and B-cell chronic lymphocytic leukemia: In addition, exogenous IL‐2 supplementation has recently been reported to restore CAR T‐cell activation in CLL,67 suggesting that cytokine support may represent an additional strategy to enhance CAR T‐cell function alongside the pharmacological and TME‐targeted interventions explored here.